2016 ROTARY INTERNATIONAL CONVENTION Family Donors are Critical and Legitimate in Developing Countries Cees Th. Smit Sibinga President RAG GNBD.

Slides:



Advertisements
Similar presentations
Survey design. What is a survey?? Asking questions – questionnaires Finding out things about people Simple things – lots of people What things? What people?
Advertisements

The National Council on Economic Education/John Templeton Foundation Teaching the Ethical Foundations of Economics Lesson 7: Should We Allow a Market For.
Carla Peterson, President Elect ADRP International Blood Safety Forum, March 20, 2015 A Global Network Dedicated to SHARING Information to Improve the.
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013.
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
Pre and Post Donation Counselling
Epidemiology and Control Programs for HBV Infection. Yousef Qari, MD, FRCP(C), ABIM Gastoenterologist King Abdulaziz University Hospital.
Why "We" should Care Presented to: International Blood Safety Forum Jed Gorlin MD, MBA March 20, 2015 ©2015 Innovative Blood Resources, Proprietary & Confidential.
“ One small step for a man, a giant leap for mankind; - But the step is still to be taken" - The challenges of building a safe repeat donor pool “ One.
Role of Clinicians in Promoting Voluntary Blood Donation Dr. Anju Verma.
Management of Risk and Blood Availability in Donor Populations with High Prevalence of Blood Borne Pathogens Ravi Reddy IBSF Meeting 20 March 2015.
Prevalence and risk relationships of tattoo, acupuncture and skin/body piercing histories among American Red Cross blood donors Sharyn Orton, MSPH, PhD.
C H I R O N Blood Testing Blood Products Advisory Committee 67th Meeting – September 14, 2000 Detection of HIV-1 p24 antigen positive donor specimens by.
European Health Forum 2003Reinhart Waneck1 Safety and Quality of Human Blood Products and Human Blood Derivatives in an Enlarged European Union The experience.
©Ian Sommerville 2004Software Engineering, 7th edition. Chapter 24 Slide 1 Critical Systems Validation 1.
Donor Counselling. Teaching Aims You should learn to counsel the donor so as to – Enhance blood safety and donor care – Minimise blood wastage – Reduce.
TRANSFUSION SAFETY AN INTERNATIONAL FLAVOR. RISK DATA – U.S. Motor cycling 1:50 20 Cigarettes/d 1:200 Hit by car 1:20,000 BC pills 1:50,000 Earthquake.
And the order changeth …. Evolving protocols for TTI testing
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.
Post-MDA surveillance ( including xeno-monitoring) Krishnamoorthy K. Vector Control Research Centre Pondicherry India.
Harold S. Margolis, M.D. Division of Viral Hepatitis
World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
With the forthcoming introduction of deemed consent in Wales in December 2015, is presumed (deemed) consent the future for organ donation in England? Claudia.
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-
Ensuring the Fundamentals of Care in Family Planning and Reproductive Health Services MODULE 2 Facilitative Supervision for Quality Improvement Curriculum.
The approach taken by a Central/Eastern European Blood Transfusion Organisation: POLAND Magdalena Łętowska National Centre for Transfusion Medicine Warsaw,
Beyond the Pale: the Ethics of Gifts Professor Andrew Zolani Cakana (FIBMS; MB ChB; CTM; M Med Sc.; FRCPath).
UNITED BLOOD SERVICES The Trima Accel Collection System.
Safe Immunization Practices and Prevention of Hepatitis B and C Susan Mackay Behaviour Change Project Safe Injection Global Network.
Blood An essential ingredient in medical treatment Has no synthetic substitute Voluntary blood donors - the only source 3.
Statistical Hypotheses & Hypothesis Testing. Statistical Hypotheses There are two types of statistical hypotheses. Null Hypothesis The null hypothesis,
Our tryst with Nucleic Acid Testing Dolly Daniel, Dept of Transfusion Medicine, CMC, Vellore.
Population Issues. Table of Contents 1. Overpopulation 2. Population Control 3. Population Futures.
Proposal to Align OPTN Policies with the 2013 PHS Guideline for Reducing Transmission of HIV, HBV, and HCV Through Solid Organ Transplantation Ad Hoc Disease.
Epidemiology of Transfusion Transmitted Disease Sharyn Orton, MT(ASCP)SBB, M.S.P.H, Ph.D. candidate Project Leader, Transmissible Diseases Department American.
Vaccines & Biologicals (V&B) Cost-effectiveness of safe injection policies: Study rationale and proposed methodology Ulla Kou, WHO SIGN meeting in New.
Topic 1: FDA Draft Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” Dorothy.
Preventing Maternal and Infant Mortalities What GNBD Can Do.
Bad Blood? An Investigation of the MSM Ban on Blood Donation Lauren Lacy Abstract In 1983, the Food and Drug Administration (FDA), responding to the AIDS.
2016 ROTARY INTERNATIONAL CONVENTION Global Overview of Blood Donor Motivation and Mobilization Cees Th. Smit Sibinga President RI RAG GNBD.
10th PAN ARAB BLOOD TRANSFUSION CONFERENCE
BLOOD donation.
HIV and HBV Infection, Knowledge and Risk Behaviour in Ghanaian Prisons
Government of Swaziland
O D Negative Red Cells.
Case Consultation.
Implementing NAT& Universal Parasitic Screening for Blood Donors
“Girls in mining” Based on research carried out between April and December 2006 by the International Labour Organization’s International Programme on the.
Global Network for Blood Donation
Higher Prevalence of HbsAg among Blood Donors at a tertiary care center in greater Gwalior: A 5years study ( TTI-12 : D-1182 ) Dr. Anita Arya, Dr. Sachin.
Saudi public awareness, attitude and practices of blood donation
Violence against Women Indicators on scope, prevalence and incidence
Research Methods Assignment 2
Problems with Kohlberg’s method
11/20/2018 Study Types.
Governor’s Challenge.
Viral Safety of Blood Products in Taiwan
Viral Hepatitis Prevention Board Secretariat
Resolution concerning statistics of Work, Employment & labour underutilization
Marketing: the consumer
Goal Identification Identify what the you raise will support. Flight
Let us bridge blood shortage
INTRODUCTION The International Society of Blood Transfusion (ISBT) recognizes more than 300 Red Blood Cell (RBC) antigens that belong to 35 different recognized.
Dr. Nishi Jaswal Assistant Professor
Figure 2 Distribution of markers of active HBV infection
Audit Principles Kevin Alder Agenda 8.2 ET-WISC-DC2019
World Health Organization
Presentation transcript:

2016 ROTARY INTERNATIONAL CONVENTION Family Donors are Critical and Legitimate in Developing Countries Cees Th. Smit Sibinga President RAG GNBD

Safety of the Gift of Life to the World Viral Marker Prevalence Is there a difference between FADs and first time VNRDs?

 Family/acquaintance blood donors (FAD) considered less safe than voluntary non-remunerated blood donors (VNRD);  Pressure and coercion are considered unethical. Assumptions – 3

 FAD are actively discouraged by international organizations (IO);  Affluent countries support these IO;  Existing shortages continues. Consequence – 4

 Viral marker data of 1st time VNRD and FAD, corrected for gender and age show, no significant difference;  Basic motive for VNRD and FAD is benevolence rather than altruism;  FADs are willing to become VNRD and to repeat donation if asked. Viral Markers 5

Type of DonorsN DonorsConfirmed Anti-HIV (%) HBsAG (%)Confirmed Anti-HCV (%) FAD17,449 (68.3%) 550 (3.2)2521 (14.4)583 (3.3) VNR8094 (31.7%) 110 (1.4)1027 (12.7)248 (3.1) First time (2.0)824 (16.8)223 (4.5) Regular (0.4)203 (6.4)25 (0.8) Prevalence in VNR and FA blood donors in Mali – HIV, HBV, HCV From: J-P Allain – ISBT Science Series 2010;5:

Viral Markers CountryType of DonorsN Donorsconfirmed HIV (%)HBsAg (%) CamerounFirst time VNRD (4.0)49 (18.0) FAD (3.7) 233 (7.6) GhanaFirst time VNRD (1.0)919 (13.8) FAD (1.1)649 (14.8) GuineaFirst time VNRD (1.6)259 (14.5) FAD (0.5)1142 (12.8) Prevalence of HIV and HBV in first time VNR and FA donors From: J-P Allain – ISBT Science Series 2010;5:

FAD in the Blood Supply in Four Continents AmericasAfricaAsiaEurope <20%20-79%>80% ArgentinaBeninAlgeriaAngolaChinaAlbania BoliviaBotswanaBurk. FasoCameroonIndiaGreece BrazilBurundiErytreaChadIranMontenegr ChileCARGambiaCongoKuwait ColumbiaCôte d’Iv.GuineaDRCKSA Cost. RicaMalawiKenyaEthiopiaOman CubaNamibiaMoroccoGabonPakistan EcuadorSouth Afr.Mozamb.GhanaThailand El SalvadorRuandaTunisiaGuin. Biss.Turkey GuatamSenegalZambiaMadagasc. HondurasUgandaMali 8

FAD in the Blood Supply in Four Continents (2) AmericasAfricaAsiaEurope <20%20-79%>80% JamaicaMauritania MexicoSierra Leo NicaraguaTanzania Paraguay Peru Surinam Uruguay Venezuela 9

TTI Marker Prevalence in non-SSA Countries post-2009 countrydonors% prevalence Anti-HIVAnti-HCVHBsAg ft VNRDFADft VNRDFADft VNRDFAD Albania52, India47, , Nepal33, Pakistan13, Thailand? Ghana6, Camer Mozamb

Family/Acquaintance Donors  FAD are almost exclusively called upon in countries with considerable blood shortages  In life-threatening situations due to severe shortage, pressures are extended on both VNRD and FAD  FAD blood are cheaper than ‘one time only’ VNRD 11

Statements 1. FADs meet all basic criteria of VNRD; 2. FAD remain a critical source of (regular) VNR blood; 3. At this point in time, FADs are - legitimate and indispensable - should not be discouraged. 12

However – 4. FAD should be encouraged to become regular VNR donors; 5. FAD are a good potential to bridge the gap to reach 100% VNRD. Statements 13

Evidence Base - GNBD Study Proposal There are limited comparitive and reliable studies available to provide a solid evidence base. Objective– To re-open the assessment (evidence base) on whether the ban on FAD in developing countries is justified. 14

Evidence Base - GNBD Study Proposal Developing countries –  Selected countries from Low and Medium HDI (4 continents);  Demographic, logistic and statistical data collection on - blood donor typology (first time VNRD & FAD) ; 15

Evidence Base - GNBD Study Proposal - viral marker epidemiology (TTI marker prevalence) ; - frequency of blood donation (% regular vs first time/one time only for VNRD and FAD); - blood usage/consumption and suppl (supply or demand driven); 16

Evidence Base - GNBD Study Proposal  Focus on 1st time/one time only VNR and FAD donation;  Collection of (confirmed) TTI marker prevalence;  Correction for gender and age;  N = to be determined (statistical significance). 17

Message from RAG GNBD Be a Gift to the World Donate BLOOD on a voluntary and non- remunerated principle Preferably do that regularly! 18